Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants
Overview
Authors
Affiliations
The COVID-19 pandemic continues to be a severe threat to human health, especially due to current and emerging SARS-CoV-2 variants with potential to escape humoral immunity developed after vaccination or infection. The development of broadly neutralizing antibodies that engage evolutionarily conserved epitopes on coronavirus spike proteins represents a promising strategy to improve therapy and prophylaxis against SARS-CoV-2 and variants thereof. Herein, a facile multivalent engineering approach is employed to achieve large synergistic improvements in the neutralizing activity of a SARS-CoV-2 cross-reactive nanobody (VHH-72) initially generated against SARS-CoV. This synergy is epitope specific and is not observed for a second high-affinity nanobody against a non-conserved epitope in the receptor-binding domain. Importantly, a hexavalent VHH-72 nanobody retains binding to spike proteins from multiple highly transmissible SARS-CoV-2 variants (B.1.1.7 and B.1.351) and potently neutralizes them. Multivalent VHH-72 nanobodies also display drug-like biophysical properties, including high stability, high solubility, and low levels of non-specific binding. The unique neutralizing and biophysical properties of VHH-72 multivalent nanobodies make them attractive as therapeutics against SARS-CoV-2 variants.
Next generation single-domain antibodies against respiratory zoonotic RNA viruses.
Swart I, Van Gelder W, de Haan C, Bosch B, Oliveira S Front Mol Biosci. 2024; 11:1389548.
PMID: 38784667 PMC: 11111979. DOI: 10.3389/fmolb.2024.1389548.
Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.
Rizk S, Moustafa D, ElBanna S, Nour El-Din H, Attia A World J Microbiol Biotechnol. 2024; 40(7):209.
PMID: 38771414 PMC: 11108896. DOI: 10.1007/s11274-024-03990-4.
Wang J, Shi B, Chen H, Yu M, Wang P, Qian Z Vaccines (Basel). 2024; 12(4).
PMID: 38675799 PMC: 11054741. DOI: 10.3390/vaccines12040417.
Qin Q, Jiang X, Huo L, Qian J, Yu H, Zhu H J Nanobiotechnology. 2024; 22(1):58.
PMID: 38341574 PMC: 10858482. DOI: 10.1186/s12951-024-02329-3.
Merwaiss F, Lozano-Sanchez E, Zulaica J, Rusu L, Vazquez-Vilar M, Orzaez D Plant Biotechnol J. 2023; 22(4):876-891.
PMID: 37966715 PMC: 10955499. DOI: 10.1111/pbi.14230.